Key statistics
As of last trade PAVmed Inc (1P50:BER) traded at 0.00, -100.00% above its 52-week low of 2.44, set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 10.41m |
Free float | 9.33m |
P/E (TTM) | -- |
Market cap | 11.66m USD |
EPS (TTM) | -8.17 USD |
Data delayed at least 15 minutes, as of Dec 07 2023 07:32 GMT.
More ▼
Press releases
- Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
- Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
- Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
- PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
- Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
- PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
- Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
- Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
- Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
More ▼